CHChun Hu

Chun Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chun Hu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Fuyou Liu

    Department of Nephrology, Second Xiangya Hospital, Central South University, Changsha, China

    1 shared publication
  • Li Xiao

    Department of Nephrology, Second Xiangya Hospital, Central South University, Changsha, China

    1 shared publication
  • Lin Sun

    Department of Nephrology, Second Xiangya Hospital, Central South University, Changsha, China

    1 shared publication
  • Ming Yang

    Department of Nephrology, Second Xiangya Hospital, Central South University, Changsha, China

    1 shared publication
  • Peng Gao

    Department of Nephrology, Second Xiangya Hospital, Central South University, Changsha, China

    1 shared publication
  • Shikun Yang

    Department of Nephrology, Second Xiangya Hospital, Central South University, Changsha, China

    1 shared publication

Latest Publications

  • Effects of Omega‐3 Fatty Acids on Markers of Inflammation in Patients With Chronic Kidney Disease: A Controversial Issue

    by Chun Hu, Ming Yang, Xuejing Zhu, Peng Gao, Shikun Yang, Yachun Han, Xianghui Chen, Li Xiao, Shuguang Yuan, Fuyou Liu, et al.

    Chronic kidney disease (CKD) is a global problem which contributes to a significant morbidity and mortality in China. Concomitant inflammatory state further boosts the mortality due to cardiovascular events in patients with CKD undergoing dialysis. There is a general notion that Omega‐3 fatty acids including docosahexaenoic acids (DHA) and eicosapentaenoic (EPA) have certain health benefits perhaps via the regulation of inflammation. However, the anti‐inflammatory effect of omega‐3 fatty acids in patients with CKD is controversial. We analyzed the data of oral supplementation of omega‐3 fatty acids in CKD patients by searching literature on database from inception to August 2016. The analysis included randomized controlled trials (RCTs) derived from multiple databases, and the effect of omega‐3 fatty acids supplementation versus the control cohorts were compared. All of the data analysis was calculated by RevMan 5.2. A total of 12 RCTs involving 487 patients were included in the meta‐analysis. Among them 254 patients received omega‐3 fatty acids and 233 patients served as controls who received placebo. The meta‐analysis revealed no statistical significance in serum levels of C‐reactive protein (CRP) (SMD, −0.20; 95% CI, −0.44 to 0.05; P = 0.11), IL‐6 (SMD, 0.00; 95% CI, −0.33 to 0.33; P = 0.99) and TNF‐α (SMD, 0.14; 95% CI, −0.17 to 0.44; P = 0.38) between the omega‐3 fatty acids supplementation group and control. This suggested that there is insufficient evidence to conclude the benefit of omega‐3 fatty acids oral supplementation in reducing serum levels of CRP, IL‐6 and TNF‐α in patients with CKD.